Medizin
Refine
Year of publication
Document Type
- Article (65) (remove)
Language
- English (65)
Has Fulltext
- yes (65)
Is part of the Bibliography
- no (65)
Keywords
- apoptosis (15)
- Apoptosis (6)
- TRAIL (6)
- cell death (6)
- Smac (5)
- IAP proteins (4)
- cancer (4)
- PI3K (3)
- glioblastoma (3)
- leukemia (3)
- mitochondria (3)
- rhabdomyosarcoma (3)
- Ewing sarcoma (2)
- NF-κB (2)
- Sarcoma (2)
- autophagy (2)
- betulinic acid (2)
- immunotherapy (2)
- mitosis (2)
- neuroblastoma (2)
- proteasome inhibitor (2)
- ubiquitin (2)
- 16p11.2 (1)
- ABT-737 (1)
- Autism (1)
- Autophagy (1)
- B-cell lymphoma (1)
- BCL-2 (1)
- BRD4 (1)
- BV6 (1)
- Bcl-2 (1)
- Bioactivity-guided fractionation (1)
- Bone cancer (1)
- Bortezomib (1)
- CDK9 (1)
- CIK cells (1)
- CRISPR/Cas9 (1)
- Cancer epigenetics (1)
- Cancer genetics (1)
- Cancer therapeutic resistance (1)
- Chemotherapy (1)
- CysLTR1 (1)
- Cysteine‐Rich Domain (CRD) (1)
- DNA sequencing (1)
- DR5 (1)
- Drug development (1)
- Drug resistance (1)
- Drug therapy (1)
- ERMS (1)
- EWS/Fli1 (1)
- Epidermal growth factor receptor (1)
- Fbw7 (1)
- Feasibility (1)
- HH (1)
- HMA (1)
- HhAntag (1)
- Homeostasis (1)
- IAPs (1)
- Kynurenine (1)
- LC3B (1)
- Macroautophagy (1)
- Manatee invariant (1)
- Mathematical model (1)
- Mcl-1 (1)
- Mitochondria (1)
- NF-κB pathway (1)
- NHE (1)
- NOXA (1)
- NSG mice (1)
- PAR (1)
- PAX3/FOXO1 (1)
- PLK1 (1)
- PLK1 inhibitors (1)
- PTCH (1)
- PUMA (1)
- Petri net (1)
- Phytochemicals (1)
- Pre‐Ligand Assembly Domain (PLAD) (1)
- Quinolinate phosphoribosyltransferase (1)
- Quinolinic acid (1)
- RD cells (1)
- RH30 cells (1)
- RIP1 (1)
- RIPK3 (1)
- ROS (1)
- Rhabdomyosarcoma (1)
- Sholl analysis (1)
- Signaling pathway (1)
- Single-Molecule Localization Microscopy (SMLM) (1)
- Smac mimetic (1)
- Targeted therapies (1)
- Targeted tumor therapy (1)
- Transition invariant (1)
- USP9X (1)
- XIAP (1)
- acute myeloid leukemia (AML) (1)
- astrocytoma (1)
- autophagic cell death (1)
- cFLIP (1)
- cancer therapy (1)
- cell therapy (1)
- chemotherapy (1)
- childhood cancer (1)
- chimeric antigen receptor (1)
- combination therapy (1)
- combination treatment (1)
- cytokine-induced killer cells (1)
- doxorubicin (1)
- gene expression profiling (GEP) (1)
- glucocorticoid (1)
- hedgehog (1)
- inflammation (1)
- interferon (1)
- metastatic cancer (1)
- microtubule disruptors (1)
- microtubule-targeting agents (1)
- natural compounds (1)
- natural killer cells (1)
- necroptosis (1)
- p53 (1)
- pancreatic cancer (1)
- pediatric cancer (1)
- pictilisib (1)
- polo-like kinase 1 (1)
- preclinical (1)
- redox (1)
- rhabdomyosarcomas (1)
- second mitochondria-derived activator of caspases mimetic (1)
- signal transduction (1)
- signaling (1)
- smac mimetic (1)
- soft tissue sarcoma (1)
- sonidegib (1)
- therapeutics (1)
- tumor growth (1)
- vismodegib (1)
Institute
Autophagy in cancer therapy
(2017)
Autophagy represents a catabolic program involved in the degradation of cellular components via lysosomes. It serves to mitigate cellular stress and to provide metabolic precursors especially upon starvation. Thereby, autophagy can support the survival of cancer cells. In addition, there is now convincing evidence showing that under certain conditions autophagy can also foster cell death. This dual function of autophagy is also relevant upon anticancer treatment, as many chemotherapeutic agents engage autophagy. A better understanding of the molecular mechanisms that are critical for mediating autophagic cell death in cancer cells will be instrumental to selectively interfere with this cellular program in order to increase the cancer cell’s response to cytotoxic drugs. This review illustrates how anticancer drug-induced autophagy is involved in mediating cell death.
Ataxia-Telangiectasia (A-T), a pleiotropic chromosomal breakage syndrome, is caused by the loss of the kinase Ataxia-telangiectasia mutated (ATM). ATM is not only involved in the response to DNA damage, but also in sensing and counteracting oxidative stress. Since a disturbed redox balance has been implicated in the pathophysiology of A-T lung disease, we aimed to further explore the interplay between ATM and oxidative stress in lung cells. Using a kinetic trapping approach, we could demonstrate an interaction between the trapping mutant TRX1-CS and ATM upon oxidative stress. We could further show that combined inhibition of thioredoxin reductase (TrxR) and ATM kinase activity, using Auranofin and KU55933 respectively, induced an increase in cellular reactive oxygen species (ROS) levels and protein oxidation in lung cells. Furthermore, ATM inhibition sensitized lung cells to Auranofin-induced cell death that could be rescued by ROS scavengers. As a consequence, targeted reduction of ATM by TRX1 could serve as a regulator of oxidative ATM activation and contribute to the maintenance of the cellular redox homeostasis. These results highlight the importance of the redox-active function of ATM in preventing ROS accumulation and cell death in lung cells.
While necroptosis has for long been viewed as an accidental mode of cell death triggered by physical or chemical damage, it has become clear over the last years that necroptosis can also represent a programmed form of cell death in mammalian cells. Key discoveries in the field of cell death research, including the identification of critical components of the necroptotic machinery, led to a revised concept of cell death signaling programs. Several regulatory check and balances are in place in order to ensure that necroptosis is tightly controlled according to environmental cues and cellular needs. This network of regulatory mechanisms includes metabolic pathways, especially those linked to mitochondrial signaling events. A better understanding of these signal transduction mechanisms will likely contribute to open new avenues to exploit our knowledge on the regulation of necroptosis signaling for therapeutic application in the treatment of human diseases.
To search for novel strategies to enhance the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis pathways in glioblastoma, we used the B-cell lymphoma 2/Bcl2-like 2-inhibitor ABT-737. Here we report that ABT-737 and TRAIL cooperate to induce apoptosis in several glioblastoma cell lines in a highly synergistic manner (combination index <0.1). Interestingly, the concerted action of ABT-737 and TRAIL to trigger the accumulation of truncated Bid (tBid) at mitochondrial membranes is identified as a key underlying mechanism. ABT-737 and TRAIL cooperate to cleave BH3-interacting domain death agonist (Bid) into its active fragment tBid, leading to increased accumulation of tBid at mitochondrial membranes. Coinciding with tBid accumulation, the activation of Bcl2-associated X protein (Bax), loss of mitochondrial membrane potential, release of cytochrome-c and second mitochondria-derived activator of caspase (Smac) into the cytosol and caspase activation are strongly increased in cotreated cells. Of note, knockdown of Bid significantly decreases ABT-737- and TRAIL-mediated Bax activation and apoptosis. Also, caspase-3 silencing reduces ABT-737- and TRAIL-induced Bid cleavage and apoptosis, indicating that a caspase-3-driven, mitochondrial feedback loop contributes to Bid processing. Importantly, ABT-737 profoundly enhances TRAIL-triggered apoptosis in primary cultured glioblastoma cells derived from tumor material, underlining the clinical relevance. Also, ABT-737 acts in concert with TRAIL to suppress tumor growth in an in vivo glioblastoma model. In conclusion, the rational combination of ABT-737 and TRAIL cooperates to trigger tBid mitochondrial accumulation and apoptosis. This approach presents a promising strategy for targeting the apoptosis pathways in glioblastoma, which warrants further investigation.
Rhabdomyosarcomas are the most common pediatric soft tissue sarcoma and are a major cause of death from cancer in young patients requiring new treatment options to improve outcomes. High-risk patients include those with metastatic or relapsed disease and tumors with PAX3-FOXO1 fusion genes that encode a potent transcription factor that drives tumourigenesis through transcriptional reprogramming. Polo-Like Kinase-1 (PLK1) is a serine/threonine kinase that phosphorylates a wide range of target substrates and alters their activity. PLK1 functions as a pleiotropic master regulator of mitosis and regulates DNA replication after stress. Taken together with high levels of expression that correlate with poor outcomes in many cancers, including rhabdomyosarcomas, it is an attractive therapeutic target. This is supported in rhabdomyosarcoma models by characterization of molecular and phenotypic effects of reducing and inhibiting PLK1, including changes to the PAX3-FOXO1 fusion protein. However, as tumor re-growth has been observed, combination strategies are required. Here we review preclinical evidence and consider biological rationale for PLK1 inhibition in combination with drugs that promote apoptosis, interfere with activity of PAX3-FOXO1 and are synergistic with microtubule-destabilizing drugs such as vincristine. The preclinical effects of low doses of the PLK1 inhibitor volasertib in combination with vincristine, which is widely used in rhabdomyosarcoma treatment, show particular promise in light of recent clinical data in the pediatric setting that support achievable volasertib doses predicted to be effective. Further development of novel therapeutic strategies including PLK1 inhibition may ultimately benefit young patients with rhabdomyosarcoma and other cancers.